Skip to main content
    M

    MIRA Pharmaceuticals, Inc. Common Stock (MIRA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NASDAQ

    $0.63
    -0.03 (-4.37%)

    Market Cap: $27.73M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    MIRA Pharmaceuticals, Inc. Common Stock (MIRA) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    MIRA Pharmaceuticals, Inc. Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$10.44M, operating cash flow was -$4.66M and free cash flow was -$4.66M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$1.42M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $10.49M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2020 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Research and development$1.72M$3.31M$1.57M$2.35M$684.45K$14.65K
    Operating income-$10.49M-$8.02M-$8.53M-$7.05M-$2.15M-$67.63K
    Net income-$10.44M-$7.85M-$11.98M-$7.06M-$2.18M-$67.99K
    EBITDAN/A-$8.02M-$8.53M-$7.05M-$2.15M-$67.63K
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating income-$1.41M-$1.16M-$1.10M-$5.82M-$1.32M-$1.55M-$1.81M-$2.44M-$2.08M-$1.73M-$1.77M-$3.06M
    Net income-$1.42M-$1.21M-$1.15M-$5.98M-$1.14M-$1.54M-$1.78M-$2.40M-$2.04M-$1.69M-$1.72M-$5.79M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents of $6.35M were 57.3% of total assets of $11.09M, against total liabilities of $702.07K.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Total assets$11.09M$2.92M$4.93M$858.07K$3.36M$22.37K
    Current assets$11.06M$2.89M$4.86M$494.40K$2.91M$3.49K
    Cash and equivalents$6.35M$2.83M$4.60M$350.98K$2.81M$3.49K
    Total liabilities$702.07K$723.35K$558.10K$1.45M$1.09M$90.36K
    Short-term debtN/AN/A$5.06K$133.06K$293.06K$90.00K
    Shareholder equity$10.39M$2.20M$4.37M-$596.23K$2.26M-$67.99K
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$7.27M$8.20M$9.46M$11.09M$7.63M$868.32K$1.40M$2.92M$4.27M$3.02M$3.81M$4.93M
    Total liabilities$426.18K$40.82K$114.76K$702.07K$83.93K$298.46K$106.17K$723.35K$692.83K$796.61K$652.01K$558.10K
    Cash and equivalents$2.50M$3.61M$4.82M$6.35M$2.64M$730.48K$1.21M$2.83M$4.14M$2.82M$3.53M$4.60M
    Shareholder equity$6.84M$8.16M$9.35M$10.39M$7.55M$569.86K$1.29M$2.20M$3.57M$2.22M$3.16M$4.37M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
    Operating cash flow-$4.66M-$5.56M-$4.53M-$5.60M-$1.38M-$67.99K
    Capital expenditures$0$4$1$0$0$3
    Free cash flow-$4.66M-$5.56M-$4.53M-$5.60M-$1.38M-$68.00K
    Financing cash flow$8.18M$3.79M$8.78M$3.15M$4.18M$71.12K
    Fiscal years ended Dec 2020 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$1.30M-$1.21M-$1.20M-$1.14M-$1.10M-$799.65K-$1.63M-$1.81M-$1.84M-$863.93K-$1.05M-$1.04M
    Capital expendituresN/AN/A$3$1$4$0$3$0$0$0$4$0
    Free cash flowN/AN/A-$1.20M-$1.14M-$1.10M-$799.65K-$1.63M-$1.81M-$1.84M-$863.93K-$1.05M-$1.04M
    Last 12 quarters

    Frequently Asked Questions About MIRA

    What is MIRA Pharmaceuticals, Inc. Common Stock's annual revenue?

    MIRA Pharmaceuticals, Inc. Common Stock reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is MIRA Pharmaceuticals, Inc. Common Stock profitable?

    No. MIRA Pharmaceuticals, Inc. Common Stock reported net income of -$10.44M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does MIRA generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$4.66M minus capital expenditures of $0 produced free cash flow of -$4.66M.

    How much debt does MIRA Pharmaceuticals, Inc. Common Stock have?

    The balance sheet dated Dec 31, 2025 reported cash and equivalents of $6.35M.